US hospitals using innovative CAR - based treatments are facing additional costs because the affordable care payment system has n't evolved fast enough to compete with such ultra - expensive therapies . While the Centers for Medicare & Medicaid Services has agreed to pay hundreds of millions of dollars for the treatments , additional in - patient costs result in around a $ 200,000 loss per patient for hospitals . Further complexities are added by the fact each US state has multiple Medicaid authorities , including a call for an overhaul to the reimbursement system in favour of a sustainable model .
US hospitals using innovative CAR-T treatments are facing additional costs because the health care payment system hasn't evolved fast enough to deal with such ultra-expensive therapies. While the Centers for Medicare & Medicaid Services has agreed to pay hundreds of thousands of dollars for the drugs, additional in-patient costs result in around a $200,000 loss per patient for hospitals. Further complexities are added by the fact each US state has multiple Medicaid authorities, prompting a call for an overhaul to the reimbursement system in favour of a sustainable model.